Changes in Beneficial Ownership · 4
Prime Medicine, Inc.
PRMENASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1780950062.xml
Filing details
- Report period
- 2026-06-05
- Issuer
- Prime Medicine, Inc.
- Issuer CIK
- 0001894562
- Trading symbol
- PRME
Reporting owner 1
- Name
- Schenkein David P
- Reporting owner CIK
- 0001578200
- Relationship
- Director
- Address
- C/O PRIME MEDICINE, INC., 60 FIRST STREET, CAMBRIDGE, MA, 02141
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 3.06 | 2026-06-05 | A · Form 4 | 75,000 | A | 0 | [F1] | 2036-06-05 | Common Stock | 75,000 | 75,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.↩ 1
Signature 1
- Signed
- /s/ Ryan Brown, attorney-in-fact
- Date
- 2026-06-08
Company context
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.